Wild-type P53: Tumors Can't Stand It.
From: Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA. michael.kastan@stjude.org
Cell
- Publish Date: Mar 2007
- ISSN: 0092-8674
- Volume: 128
- Issue: 5
- Pages: 837-40
- Medium: Print
- Language: English
- Citation (JAMA): Kastan Michael B, et al. Wild-type P53: Tumors Can't Stand It.. Cell Mar 2007;128:837-40
Abstract
Most malignant tumors disrupt the p53 signaling pathway in order to grow and survive. Although many genes in addition to p53 are mutated in tumors, recent studies by Ventura et al. (2007) and Xue et al. (2007) suggest that restoring p53 function alone is sufficient to cause regression of several different tumor types in mice and thus might represent a potent therapeutic strategy to treat certain human cancers. Martins et al. (2006) also demonstrate that restoration of p53 activity results in tumor regression but add the sobering caveat that tumors may be able to quickly generate resistance by finding other ways to disrupt the p53 pathway.
Mesh Headings (Keywords): Animals, Cell Aging, Cell Proliferation, Cell Transformation, Neoplastic, Genes, p53, Humans, Mice, Neoplasms, Oncogenes, Signal Transduction, Tumor Suppressor Protein p53
Check for Full Text / PubMed Unique Identifier (PMID): 17350571
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.